Early Intervention Strategies for Dry AMD & Presbyopia


Activity Description

This course covers early intervention strategies for geographic atrophy and presbyopia, highlighting the importance of timely diagnosis, newer therapeutics that slow disease progression, and an overview of currently available pharmacological treatment options for presbyopia, including recently FDA-approved agents and guidance on patient selection.


Accreditation Statements

Sponsored by

NSUOCO



NSUOCO

Axiom Ophthalmic, LLC is a COPE-Approved Administrator.

COPELogo w AccreditationThis activity, COPE Activity Number 133117, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hours of CE.

Course # 104786-TD
Activity # 133117

COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

Release Date: 7-31-2026
Expiration Date: 07-31-2027

Target Audience

This accredited educational activity is designed for optometrists.

Grant Support Statement

This activity is supported by an unrestricted educational grant from Apellis, Carl Zeiss Meditec, and Tenpoint Therapeutics.


Faculty

Steven Ferrucci

Steven Ferrucci, OD, FAAO
  • Program Chair
  • Chief of Optometry
  • Sepulveda VA Medical Center
  • Professor, Southern California
  • College of Optometry
  • Marshall B. Ketchum University
  • Fullerton, California
Joshua Davidson headshot.updated

Joshua Davidson, OD, FAAO, FSLS
  • Williamson Eye Center
  • Baton Rouge, Louisiana
Selina McGee

Selina McGee, OD, FAAO
  • Founder & Chief Optometrist
  • BeSpoke Vision
  • Edmond, Oklahoma
Mary Beth Yackey

Mary Beth Yackey, OD
  • Cincinnati Eye Institute
  • Cincinnati, Ohio

Program Description

This course covers early intervention strategies for geographic atrophy and presbyopia, highlighting the importance of timely diagnosis, newer therapeutics that slow disease progression, and an overview of currently available pharmacological treatment options for presbyopia, including recently FDA-approved agents and guidance on patient selection.


Faculty

  • Steven Ferrucci, OD, FAAO
  • Joshua Davidson, OD, FAAO, FSLS
  • Selina McGee, OD, FAAO
  • Mary Beth Yackey, OD

Learning Objectives

After completing this course, learners will be able to:

  • Summarize the prevalence of early-stage presbyopia and the incidence and risk factors for the development of intermediate dry AMD and GA and the impact on functional and anatomical outcomes (Knowledge)
  • Compare the mechanisms of action for current and emerging pharmaceutical treatments of early-stage presbyopia based on published clinical trial data and real-world reports, and identify ideal patient candidates for the treatment options (Knowledge, Competence, Performance)
  • Integrate multimodal diagnostic strategies, including OCT-A, for early diagnosis and classification of dry AMD/GA (Competence, Performance)
  • Assess safety and efficacy data for new and emerging intermediate dry AMD and GA treatments, including complement inhibition and multiwavelength photobiomodulation, understand the importance of earlier intervention, and initiate early collaborative management with retina specialists who are utilizing these therapies (Knowledge, Competence, performance)

Credit

This enduring educational activity is eligible for 0.5 hours of COPE credit.

Progress
Axiom Learning Center © 2026 All Rights Reserved.